Gynecologic Cancers

Latest News

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.
Puxitatug Samrotecan Exhibits Efficacy in Advanced/Metastatic EC

March 16th 2025

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.

A slightly higher complete response rate was observed with the metformin regimen vs with the levonorgestrel-releasing IUD alone in endometrial cancer.
Metformin Plus IUD Well-Tolerated in EIN/Endometrial Cancer

March 16th 2025

No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.
Hysteroscopic Resection Safely Preserves Fertility in Endometrial Cancer

March 16th 2025

Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
Mirvetuximab Soravtansine Sustains OS Benefit in FRα+ PROC

March 16th 2025

Avutometinib/Defactinib Shows Promise in Advanced Mesonephric Gynecologic Cancer
Avutometinib/Defactinib Shows Promise in Advanced Mesonephric Gynecologic Cancer

March 16th 2025

Video Series
Video Interviews
Podcasts
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

More News